Do you want to read an article? Please log in or register.
Lipid lowering agents of natural origin: An account of some promising chemotypes
Related content
RECOMMENDED
HypertensionLipid-Lowering DrugsThrombosis and Stroke
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Lancet.
Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P
doi: 10.1016/S0140-
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
JAMA Cardiol.
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ
doi: 10.1001/
Lipid-Lowering Drugs
An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals
Eur Heart J Acute Cardiovasc Care.
Buonvino C, Chopard R, Guillon B, Puymirat E, Farnier M, Ferrières J, Krempf M, Bruckert E, Meneveau N, Schiele F
doi: 10.1177/2048872620912639.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Circulation.
Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS
doi: 10.1161/
Lipid-Lowering Drugs
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
Clin Chem Lab Med.
Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.
doi: 10.1515/cclm-2019-1253.
Lipid-Lowering Drugs
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Hypertension.
Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM
doi: 10.1161/
COMMENTED
Lipid-Lowering Drugs
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
★ 3
Recommended and commented by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1016/j.atherosclerosis.2019.12.005.
Lipid-Lowering Drugs
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
JAMA.
Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL
doi: 10.1001/jama.2018.20045.
Lipid-Lowering Drugs
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry
J Am Heart Assoc.
Xian Y, Navar AM, Li S, Li Z, Robinson J, Virani SS, Louie MJ, Koren A, Goldberg A, Roger VL, Wilson PWF, Peterson ED, Wang TY
doi: 10.1161/JAHA.119.013229.